In a study published by Siddiqi et al in The Lancet, researchers evaluated the efficacy and safety of lisocabtagene maraleucel in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Question 1 of 5
What was the primary endpoint in the TRANSCEND CLL 004 study?
